Skip to main
TIL
TIL logo

Instil Bio (TIL) Stock Forecast & Price Target

Instil Bio (TIL) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 20%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

Instil Bio Inc., a clinical-stage biopharmaceutical company, is experiencing significant momentum due to its innovative pipeline of tumor infiltrating lymphocyte (TIL) therapies, particularly with the promising data emerging from the HARMONi-2 study, which previously resulted in a substantial stock price surge. The potential for upside remains strong, as the company is strategically positioned to expand its technology into additional indications, bolstered by an estimated firm value of approximately $884 million derived from discounted cash flow analysis, indicating robust future growth prospects. Furthermore, Instil Bio's unique approach to combining checkpoint inhibition with anti-angiogenesis therapies places it at the forefront of the biopharmaceutical landscape, enhancing its competitive advantage and increasing confidence among investors.

Bears say

Instil Bio Inc reported a substantial net loss of $1.82 per share in the fourth quarter of 2024 and projects an alarming increase to $11.51 per share for the full year of 2025, reflecting a significant deterioration in financial performance. The company faces considerable risks, including potential delays in clinical advancement of key candidates and the possibility of unfavorable clinical data, particularly concerning AXN-2510 in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Additionally, there is a looming concern regarding medium- to long-term dilution risk, which could adversely impact shareholder value.

Instil Bio (TIL) has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 20% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Instil Bio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Instil Bio (TIL) Forecast

Analysts have given Instil Bio (TIL) a Buy based on their latest research and market trends.

According to 5 analysts, Instil Bio (TIL) has a Buy consensus rating as of Aug 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Instil Bio (TIL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.